Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments

Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments

Medullary thyroid carcinoma (MTC) arises from parafollicular cells in the thyroid gland, and although rare, it represents an aggressive type of thyroid cancer. MTC is recognized for its low mutational burden, with point mutations in <i>RET</i> or <i>RAS</i> genes being the mo...

Full description

Bibliographic Details
Main Authors:	Rui Sousa Martins, Tito Teles Jesus, Luís Cardoso, Paula Soares, João Vinagre
Format:	Article
Language:	English
Published:	MDPI AG 2023-07-01
Series:	Journal of Personalized Medicine
Subjects:	MTC <i>RET</i> signaling pathways TKIs multikinase inhibitors <i>RET</i>-specific inhibitors
Online Access:	https://www.mdpi.com/2075-4426/13/7/1132

Similar Items

2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer
by: V V Voskoboynikov, et al.
Published: (2013-06-01)

Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine
by: Antonio Matrone, et al.
Published: (2022-03-01)

RET mutations in a large indian family with medullary thyroid carcinoma
by: D M Mahesh, et al.
Published: (2014-01-01)

Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the <i>RET</i>
by: Nicolas Sahakian, et al.
Published: (2023-10-01)

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
by: Fallahi P, et al.
Published: (2019-08-01)

Modifier Role of Common <i>RET</i> Variants in Sporadic Medullary Thyroid Carcinoma
by: Anna Skalniak, et al.
Published: (2021-10-01)

A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC
by: Justin F. Gainor, MD, et al.
Published: (2020-09-01)

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue
by: Shinkichi Takamori, et al.
Published: (2021-08-01)

Genetic alterations in a primary medullary thyroid carcinoma and its lymph node metastasis in a patient with 15 years follow-up
by: González-Yebra Beatriz, et al.
Published: (2012-06-01)

Selective RET Inhibitors (SRIs) in Cancer: A Journey from Multi-Kinase Inhibitors to the Next Generation of SRIs
by: Liz Clark, et al.
Published: (2023-12-01)

Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma
by: Margherita Nannini, et al.
Published: (2022-12-01)

<i>RET</i>-Altered Cancers—A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity
by: Antoine Desilets, et al.
Published: (2023-08-01)

Higher <i>RET</i> Gene Expression Levels Do Not Represent anAlternative <i>RET</i> Activation Mechanism in Medullary Thyroid Carcinoma
by: Chiara Mulè, et al.
Published: (2021-10-01)

Calcitonin testing in patients with thyroid nodules for screening medullary thyroid carcinoma: a “gray zone”
by: N. V. Severskaya, et al.
Published: (2022-08-01)

Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma
by: Larissa V. Bim, et al.
Published: (2019-07-01)

RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency
by: Teresa Ramone, et al.
Published: (2020-12-01)

Precision oncology for RET-related tumors
by: Antonella Verrienti, et al.
Published: (2022-08-01)

Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea
by: Han-Sang Baek, et al.
Published: (2023-03-01)

Genetic risk association of CDKN1A and RET gene SNPs with medullary thyroid carcinoma: Results from the largest MTC cohort and meta‐analysis
by: Vasudha Mishra, et al.
Published: (2019-10-01)

Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer
by: Rui Wan, et al.
Published: (2024-01-01)

Results and Clinical Interpretation of Germline <i>RET</i> Analysis in a Series of Patients with Medullary Thyroid Carcinoma: The Challenge of the Variants of Uncertain Significance
by: Giovanni Innella, et al.
Published: (2020-11-01)

RET Proto-Oncogene Variants in Patients with Medullary Thyroid Carcinoma from the Mediterranean Basin: A Brief Report
by: Vassos Neocleous, et al.
Published: (2023-06-01)

Medullary Thyroid Carcinoma and Associated Endocrinopathies in Slovenia from 1995 to 2021
by: Sara Milicevic, et al.
Published: (2022-07-01)

Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC
by: Elisa De Carlo, et al.
Published: (2024-02-01)

RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report
by: Tongyi Zhang, et al.
Published: (2023-04-01)

RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation
by: Takuo Hayashi, et al.
Published: (2021-02-01)

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
by: Zhichao Tian, et al.
Published: (2020-08-01)

Medullary Thyroid Carcinoma Mutational Spectrum Update and Signaling-Type Inference by Transcriptional Profiles: Literature Meta-Analysis and Study of Tumor Samples
by: Emanuela Minna, et al.
Published: (2022-04-01)

Setting up a Bioluminescence Resonance Energy Transfer high throughput screening assay to search for protein/protein interaction inhibitors in mammalian cells.
by: Cyril eCouturier, et al.
Published: (2012-09-01)

An audit of medullary thyroid carcinoma from a tertiary care hospital in northwest India
by: Ananda Mohan Chakraborty, et al.
Published: (2024-01-01)

An Introduction to Managing Medullary Thyroid Cancer
by: de Groot Jan, et al.
Published: (2006-07-01)

A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer
by: Cristina Romei, et al.
Published: (2021-02-01)

Molecular Basis of Medullary Thyroid Carcinoma: The Role of RET Polymorphisms
by: Ana Luiza Maia, et al.
Published: (2011-12-01)

Significance of laboratory markers in the diagnosis and postoperative monitoring of patients with medullary thyroid cancer
by: L. A. Ivanova, et al.
Published: (2014-10-01)

Characterization of LDD-2633 as a Novel RET Kinase Inhibitor with Anti-Tumor Effects in Thyroid Cancer
by: Hyo Jeong Lee, et al.
Published: (2021-01-01)

Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection
by: Qin Huang, et al.
Published: (2020-05-01)

RET/PTC translocations and clinico-pathological features in human papillary thyroid carcinoma (PTC)
by: Cristina eRomei, et al.
Published: (2012-04-01)

Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with <i>RET</i> Rearrangements
by: Subba R. Digumarthy, et al.
Published: (2020-03-01)

Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model
by: Silvia Carra, et al.
Published: (2021-03-01)

Combination of targeted multikinase inhibitor and radioiodine: a new strategy of treatment for advanced differentiated thyroid carcinoma
by: LIU Wei
Published: (2023-11-01)